DJIA 17,888.35 168.43 0.95%
NASDAQ 5,156.31 47.64 0.93%
S&P 500 2,102.63 22.22 1.07%
market minute promo


290.04 3.18 (1.11%)

REAL-TIME: Last trade at

Extended Hours: $290.30 $0.26 (0.09%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

BIIB $290.04 1.11%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $289.30
Previous Close $286.86
Daily Range $285.80 - $290.59
52-Week Range $254.00 - $480.18
Market Cap $64.7B
P/E Ratio 18.75
Dividend (Yield) $0.00 (0.0%)
Volume 1,684,155
Average Daily Volume 2,643,098
Current FY EPS $16.57




Drug Makers

Biogen (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary Rss Feed

The World's Largest Investing Firm Bought These 2 Biotech Stocks: Should You?

BlackRock purchased shares of both Biogen and Celgene last quarter. Is it time for retail investors to do the same?

Jim Cramer -- Demand More From IBM Than Buffett Does; Be Choosy With Biotech

There's a 0.0000000000028% Chance This Drug Doesn't Work

Statistics favor Gilead Sciences' Zydelig by a wee bit.

Bristol-Myers' Cancer Drug Opdivo Gets CRL from the FDA

A $26 Billion Hedge Fund Just Bought 9 Million Shares of This Stock: Should You Follow?

Viking Global's 13-F shows that the fund made a very interesting stock buy -- should you hop in, as well?

The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros

Bristol-Myers' Opdivo Gets FDA Nod for Another Indication

BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel

Short Sellers Run for Cover From Major Biotechs

Bristol-Myers' Opdivo Label Now Includes Renal Cell Cancer

See More BIIB News...

BIIB's Top Competitors

BIIB $290.04 (1.11%)
Current stock: BIIB
AMGN $161.98 (0.55%)
Current stock: AMGN
GILD $105.85 (-0.10%)
Current stock: GILD
$0.00 (0.00%)
Current stock: